Xavier Mulet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11112051/publications.pdf

Version: 2024-02-01

28 papers	1,720 citations	471509 17 h-index	501196 28 g-index
28 all docs	28 docs citations	28 times ranked	2018 citing authors

#	Article	IF	Citations
1	Impact of Peptidoglycan Recycling Blockade and Expression of Horizontally Acquired Î²-Lactamases on Pseudomonas aeruginosa Virulence. Microbiology Spectrum, 2022, 10, e0201921.	3.0	8
2	Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 279-282.	0.5	4
3	Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2021, 39, 279-282.	0.3	2
4	Emergence of Resistance to Novel Cephalosporinâ€“Î²-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump. Antimicrobial Agents and Chemotherapy, 2021, 65, e0008921.	3.2	29
5	In Vivo Evolution of GES Î²-Lactamases Driven by Ceftazidime/Avibactam Treatment of Pseudomonas aeruginosa Infections. Antimicrobial Agents and Chemotherapy, 2021, 65, e0098621.	3.2	14
6	Whole-genome sequence-guided PCR for the rapid identification of thePseudomonas aeruginosaST175 high-risk clone directly from clinical samples. Journal of Antimicrobial Chemotherapy, 2021, 76, 945-949.	3.0	2
7	Multicenter Performance Evaluation of MALDI-TOF MS for Rapid Detection of Carbapenemase Activity in Enterobacterales: The Future of Networking Data Analysis With Online Software. Frontiers in Microbiology, 2021, 12, 789731.	3.5	4
8	WGS characterization of MDR Enterobacterales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain. JAC-Antimicrobial Resistance, 2020, 2, dlaa084.	2.1	7
9	Characterization of AmpC Î²-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 474-478.	0.5	13
10	Characterization of AmpC Î²-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 474-478.	0.3	1
11	O-antigen serotyping and MALDI-TOF, potentially useful tools for optimizing semi-empiric antipseudomonal treatments through the early detection of high-risk clones. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 541-544.	2.9	17
12	Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study. International Journal of Antimicrobial Agents, 2019, 53, 682-688.	2.5	37
13	Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2018, 73, 658-663.	3.0	157
14	Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2191-2200.	2.9	53
15	Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegansPseudomonas aeruginosa Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	39
16	In Vivo Emergence of Resistance to Novel Cephalosporinâ€“Î²-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 Î²-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	61
17	VIM-47, a New Variant of the Autochthonous Metallo-Î²-Lactamase VIM-13 from the Balearic Islands in Spain. Antimicrobial Agents and Chemotherapy, 2016, 60, 3251-3252.	3.2	3
18	The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resistance Updates, 2015, 21-22, 41-59.	14.4	475

#	Article	IF	Citations
19	Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC. Antimicrobial Agents and Chemotherapy, 2014, 58, 3091-3099.	3.2	197
20	Overexpression of MexCD-OprJ Reduces Pseudomonas aeruginosa Virulence by Increasing Its Susceptibility to Complement-Mediated Killing. Antimicrobial Agents and Chemotherapy, 2014, 58, 2426-2429.	3.2	23
21	The Pseudomonas aeruginosa CreBC Two-Component System Plays a Major Role in the Response to Î²-Lactams, Fitness, Biofilm Growth, and Global Regulation. Antimicrobial Agents and Chemotherapy, 2014, 58, 5084-5095.	3.2	56
22	Molecular Epidemiology and Multidrug Resistance Mechanisms of Pseudomonas aeruginosa Isolates from Bulgarian Hospitals. Microbial Drug Resistance, 2013, 19, 355-361.	2.0	45
23	Biological Markers of Pseudomonas aeruginosa Epidemic High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2013, 57, 5527-5535.	3.2	104
24	Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in Pseudomonas aeruginosa Cystic Fibrosis Chronic Lung Infection. PLoS ONE, 2013, 8, e71001.	2.5	69
25	Antagonistic Interactions of Pseudomonas aeruginosa Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm Growth. Antimicrobial Agents and Chemotherapy, 2011, 55, 4560-4568.	3.2	58
26	Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. Journal of Antimicrobial Chemotherapy, 2011, 66, 2022-2027.	3.0	132
27	Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. Journal of Antimicrobial Chemotherapy, 2010, 65, 1399-1404.	3.0	37
28	Azithromycin in Pseudomonas aeruginosa Biofilms: Bactericidal Activity and Selection of nfxB Mutants. Antimicrobial Agents and Chemotherapy, 2009, 53, 1552-1560.	3.2	73